162 Safety and Efficacy of Apixaban in Patients Receiving Hemodialysis Compared to Patients with Moderate Renal Dysfunction

Introduction: Apixaban is FDA approved for use in patients with end stage renal disease (ESRD). Patients with ESRD were excluded from the phase three clinical trials, therefore dosing is based on single-dose pharmacokinetic and pharmacodynamic studies and extrapolated to be similar results to patients with moderate renal dysfunction (CrCl 30-50 mL/min). This study aims to determine if the safety and efficacy of apixaban in patients on dialysis is similar to patients with moderate renal dysfunction.